Characterization of a novel, trastuzumab resistant human breast cancer cell line

Mark Barok, M. Balázs, Viktoria Lazar, Z. Rákosy, Eniko Toth, Andrea Treszl, G. Vereb, Gail T. Colbern, John W. Park, J. Szöllősi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

HER2-positive breast cancers represent a distinct phenotype and are intrinsically more aggressive than HER2-negative tumors. Although HER2-targeted therapies have been rationally developed, resistance to these treatments represents a process understood poorly. There are few experimental models that allow studying the molecular mechanism of resistance. Our aim was to characterize a trastuzumab resistant breast cancer cell line (B585) that was established from an invasive ductal carcinoma. B585 grows only in immunodeficient mice as a xenograft. CGH and FISH were used to define cytogenetic alterations, gene-expression analysis and immunohistochemistry were applied to detect RNA and protein expression. By array-CGH focused amplifications were identified for C-MYC, EGFR, ErbB2, CCND1 and TOP2-A oncogenes. ErbB2 was co-amplified with TOP2-A. mRNA overexpression was detected for the amplified genes. ErbB2 protein was overexpressed and showed heterogeneous distribution. In summary, molecular cytogenetic analysis and expression profiling of B585 revealed several new alterations. Based on the experiments performed in SCID mice and the genotypic/phenotypic characteristics, this new in vivo breast cancer xenograft is a valuable model to investigate molecular mechanism of trastuzumab resistance.

Original languageEnglish
Pages (from-to)627-640
Number of pages14
JournalFrontiers in bioscience (Elite edition)
Volume2 E
Issue number2
Publication statusPublished - Jan 1 2010

Fingerprint

Heterografts
Cells
Breast Neoplasms
Cell Line
Gene expression
Amplification
Tumors
Ductal Carcinoma
Proteins
SCID Mice
Genes
Cytogenetic Analysis
RNA
Oncogenes
Cytogenetics
Messenger RNA
Theoretical Models
Immunohistochemistry
Phenotype
Gene Expression

Keywords

  • Array-CGH
  • Breast tumor xenograft
  • Drug resistance
  • ErbB2/HER-2
  • Gene and protein expression
  • Trastuzumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Characterization of a novel, trastuzumab resistant human breast cancer cell line. / Barok, Mark; Balázs, M.; Lazar, Viktoria; Rákosy, Z.; Toth, Eniko; Treszl, Andrea; Vereb, G.; Colbern, Gail T.; Park, John W.; Szöllősi, J.

In: Frontiers in bioscience (Elite edition), Vol. 2 E, No. 2, 01.01.2010, p. 627-640.

Research output: Contribution to journalArticle

Barok, Mark ; Balázs, M. ; Lazar, Viktoria ; Rákosy, Z. ; Toth, Eniko ; Treszl, Andrea ; Vereb, G. ; Colbern, Gail T. ; Park, John W. ; Szöllősi, J. / Characterization of a novel, trastuzumab resistant human breast cancer cell line. In: Frontiers in bioscience (Elite edition). 2010 ; Vol. 2 E, No. 2. pp. 627-640.
@article{7308d8f9a2eb419799acf34f94ea9a4a,
title = "Characterization of a novel, trastuzumab resistant human breast cancer cell line",
abstract = "HER2-positive breast cancers represent a distinct phenotype and are intrinsically more aggressive than HER2-negative tumors. Although HER2-targeted therapies have been rationally developed, resistance to these treatments represents a process understood poorly. There are few experimental models that allow studying the molecular mechanism of resistance. Our aim was to characterize a trastuzumab resistant breast cancer cell line (B585) that was established from an invasive ductal carcinoma. B585 grows only in immunodeficient mice as a xenograft. CGH and FISH were used to define cytogenetic alterations, gene-expression analysis and immunohistochemistry were applied to detect RNA and protein expression. By array-CGH focused amplifications were identified for C-MYC, EGFR, ErbB2, CCND1 and TOP2-A oncogenes. ErbB2 was co-amplified with TOP2-A. mRNA overexpression was detected for the amplified genes. ErbB2 protein was overexpressed and showed heterogeneous distribution. In summary, molecular cytogenetic analysis and expression profiling of B585 revealed several new alterations. Based on the experiments performed in SCID mice and the genotypic/phenotypic characteristics, this new in vivo breast cancer xenograft is a valuable model to investigate molecular mechanism of trastuzumab resistance.",
keywords = "Array-CGH, Breast tumor xenograft, Drug resistance, ErbB2/HER-2, Gene and protein expression, Trastuzumab",
author = "Mark Barok and M. Bal{\'a}zs and Viktoria Lazar and Z. R{\'a}kosy and Eniko Toth and Andrea Treszl and G. Vereb and Colbern, {Gail T.} and Park, {John W.} and J. Sz{\"o}llősi",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "2 E",
pages = "627--640",
journal = "Frontiers in Bioscience - Elite",
issn = "1945-0494",
publisher = "Frontiers in Bioscience",
number = "2",

}

TY - JOUR

T1 - Characterization of a novel, trastuzumab resistant human breast cancer cell line

AU - Barok, Mark

AU - Balázs, M.

AU - Lazar, Viktoria

AU - Rákosy, Z.

AU - Toth, Eniko

AU - Treszl, Andrea

AU - Vereb, G.

AU - Colbern, Gail T.

AU - Park, John W.

AU - Szöllősi, J.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - HER2-positive breast cancers represent a distinct phenotype and are intrinsically more aggressive than HER2-negative tumors. Although HER2-targeted therapies have been rationally developed, resistance to these treatments represents a process understood poorly. There are few experimental models that allow studying the molecular mechanism of resistance. Our aim was to characterize a trastuzumab resistant breast cancer cell line (B585) that was established from an invasive ductal carcinoma. B585 grows only in immunodeficient mice as a xenograft. CGH and FISH were used to define cytogenetic alterations, gene-expression analysis and immunohistochemistry were applied to detect RNA and protein expression. By array-CGH focused amplifications were identified for C-MYC, EGFR, ErbB2, CCND1 and TOP2-A oncogenes. ErbB2 was co-amplified with TOP2-A. mRNA overexpression was detected for the amplified genes. ErbB2 protein was overexpressed and showed heterogeneous distribution. In summary, molecular cytogenetic analysis and expression profiling of B585 revealed several new alterations. Based on the experiments performed in SCID mice and the genotypic/phenotypic characteristics, this new in vivo breast cancer xenograft is a valuable model to investigate molecular mechanism of trastuzumab resistance.

AB - HER2-positive breast cancers represent a distinct phenotype and are intrinsically more aggressive than HER2-negative tumors. Although HER2-targeted therapies have been rationally developed, resistance to these treatments represents a process understood poorly. There are few experimental models that allow studying the molecular mechanism of resistance. Our aim was to characterize a trastuzumab resistant breast cancer cell line (B585) that was established from an invasive ductal carcinoma. B585 grows only in immunodeficient mice as a xenograft. CGH and FISH were used to define cytogenetic alterations, gene-expression analysis and immunohistochemistry were applied to detect RNA and protein expression. By array-CGH focused amplifications were identified for C-MYC, EGFR, ErbB2, CCND1 and TOP2-A oncogenes. ErbB2 was co-amplified with TOP2-A. mRNA overexpression was detected for the amplified genes. ErbB2 protein was overexpressed and showed heterogeneous distribution. In summary, molecular cytogenetic analysis and expression profiling of B585 revealed several new alterations. Based on the experiments performed in SCID mice and the genotypic/phenotypic characteristics, this new in vivo breast cancer xenograft is a valuable model to investigate molecular mechanism of trastuzumab resistance.

KW - Array-CGH

KW - Breast tumor xenograft

KW - Drug resistance

KW - ErbB2/HER-2

KW - Gene and protein expression

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=77954466624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954466624&partnerID=8YFLogxK

M3 - Article

C2 - 20036907

AN - SCOPUS:77954466624

VL - 2 E

SP - 627

EP - 640

JO - Frontiers in Bioscience - Elite

JF - Frontiers in Bioscience - Elite

SN - 1945-0494

IS - 2

ER -